Skip to main content

Market Overview

UPDATE: Canaccord Genuity Downgrades Hologic on Negative Outlook


In a report published Tuesday, Canaccord Genuity analyst Jason R. Mills downgraded the rating on Hologic (NASDAQ: HOLX) from Buy to Hold, and lowered the price target from $26.00 to $19.00.

In the report, Canaccord Genuity noted, “HOLX's commentary at fall brokerage meetings portended a flattish outlook for FY14, but actual '14 guidance on the Q4 call painted an even worse picture of current fundamentals, in our view. While we recognize management is likely attempting to mitigate quarterly misses and suggested FY15 should stabilize, we think growth will remain challenged, thus we downgrade to HOLD and lower our price target to $19, based on our five-year DCF, which uses a generous 14x terminal multiple (notwithstanding low/mid-single-digit FCF CAGR) and 7% discount rate. We would not be constructive buyers unless weakness is significant.”

Hologic closed on Monday at $22.90.

Latest Ratings for HOLX

Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020NeedhamDowngradesBuyHold

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Canaccord Genuity Jason R. MillsAnalyst Color Downgrades Analyst Ratings

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at